Cyclobenzaprine extended release for acute low back and neck pain

Therapy

Volumn 6, Issue 6, 2009, Pages 871-881

  Weil, Arnold J ^a  

^a Non Surgical Orthopaedics PC   (United States)

Author keywords

Central muscle relaxants; Cyclobenzaprine; Low back pain; Neck pain; Nneuromuscular agents

Indexed keywords

CYCLOBENZAPRINE; DIAZEPAM; MUSCLE RELAXANT AGENT; PLACEBO;

CLINICAL TRIAL; DISEASE DURATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; HUMAN; IMMEDIATE DRUG RELEASE; LOW BACK PAIN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NECK PAIN; REVIEW; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; XEROSTOMIA;

EID: 70449638758     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.62     Document Type: Review

References (35)

1. Strine TW, Hootman JM: US national prevalence and correlates of low back and neck pain among adults. Arthritis Rheum. 57(4), 656-665 (2007).
2. Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D: Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine 28(11), 1195-1202 (2003). (Pubitemid 36667057)
3. Dagenais S, Caro J, Haldeman S: A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 8(1), 8-20 (2008). (Pubitemid 350299273)
4. Martin BI, Deyo RA, Mirza SK et al.: Expenditures and health status among adults with back and neck problems. JAMA 299(6), 656-664 (2008).
5. Chou R, Qaseem A, Snow V et al.: Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann. Intern. Med. 147(7), 478-491 (2007). ■ A key clinical practice guideline outlining treatment options for patients with both acute and chronic low back pain. (Pubitemid 46193208)
6. Krismer M, van Tulder M: Strategies for prevention and management of musculoskeletal conditions. Low back pain (non-specific). Best Pract. Res. Clin. Rheumatol. 21(1), 77-91 (2007).
7. van Tulder M, Becker A, Bekkering T et al.: Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. Eur. Spine J. 15(Suppl. 2), S169-S191 (2006). ■ A key clinical practice guideline outlining treatment options for patients with both acute and chronic low back pain.
8. de Vet HC, Heymans MW, Dunn KM et al.: Episodes of low back pain: a proposal for uniform definitions to be used in research. Spine 27(21), 2409-2416 (2002).
9. van Tulder MW, Assendelft WJ, Koes BW, Bouter LM: Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. Spine 22(4), 427-434 (1997).
10. Arnau JM, Vallano A, Lopez A, Pellise F, Delgado MJ, Prat N: A critical review of guidelines for low back pain treatment. Eur. Spine J. 15(5), 543-553 (2006). (Pubitemid 43747526)
11. Philadelphia Panel: Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain. Phys. Ther. 81(10), 1701-1717 (2001).
12. Childs JD, Cleland JA, Elliott JM et al.: Neck pain: Clinical practice guidelines linked to the International Classification of Functioning, Disability, and Health from the Orthopedic Section of the American Physical Therapy Association. J. Orthop. Sports Phys. Ther. 38(9), A1-A34 (2008).
13. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM: Muscle relaxants for non-specific low back pain. Cochrane Database Syst. Rev. (2), CD004252 (2003). ■ Cochrane systematic review examining the evidence for the use of skeletal muscle relaxants (SMRs) in low back pain.
14. Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom Manage. 28(2), 140-175 (2004). ■ A general systematic review of SMRs in multiple musculoskeletal conditions. (Pubitemid 38970077)
15. Beebe FA, Barkin RL, Barkin S: A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am. J. Ther. 12(2), 151-171 (2005). ■■ Important review examining the evidence for the use of SMRs in muscle spasm and the relationship between muscle spasm and pain.
16. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296-1310 (2001). (Pubitemid 32804122)
17. Browning R, Jackson JL, O'Malley PG: Cyclobenzaprine and back pain: a meta-analysis. Arch. Intern. Med. 161(13), 1613-1620 (2001). ■■ A meta-analysis of the clinical evidence for the use of cyclobenzaprine immediate release (IR) in low back and neck pain, with the overall finding of a 4.7-times greater chance of achieving an improvement of symptoms with cyclobenzaprine than with placebo.
18. Amrix® package insert. Cephalon Inc., PA, USA (2008).
19. max parameters were similar, indicating similar systemic exposure to the drug between the two regimens.
20. Darwish M, Hellriegel E, Weil A: Relationship between the pharmacokinetics and efficacy of once-daily cyclobenzaprine extended-release. Pain Med. 10(1), 260-261 (2009).
21. Hucker HB, Stauffer SC, Balletto AJ, White SD, Zacchei AG, Arison BH: Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos. 6(6), 659-672 (1978).
22. max doubled in healthy volunteers receiving 30 mg dose compared with the 15 mg dose, showing predictable dose scaling of cyclobenzaprine ER.
23. Darwish M, Xie F: Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. Clin. Drug Investig. 29(3), 145-152 (2009).
24. Darwish M , Xie F: Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. Drugs Aging 26(2), 95-101 (2009).
25. Flexeril® package insert. McNeil Consumer & Specialty Pharmaceuticals, PA, USA (2003).
26. Hucker HB, Stauffer SC, Albert KS, Lei BW: Plasma levels and bioavailability of cyclobenzaprine in human subjects. J. Clin. Pharmacol. 17(11-12), 719-727 (1977).
27. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab. Dispos. 24(7), 786-791 (1996). (Pubitemid 26244222)
28. Borenstein DG, Korn S: Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin. Ther. 25(4), 1056-1073 (2003).
29. Malanga GA, Ruoff GE, Weil AJ, Altman CA, Xie F, Borenstein DG: Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. Curr. Med. Res. Opin. 25(5), 1179-1196 (2009). ■■ Key clinical efficacy data from two clinical studies of cyclobenzaprine ER in muscle spasm associated with low back and neck pain; significant improvements in patient rating of medication helpfulness for cyclobenzaprine ER versus placebo (30 mg in study 1, p = 0.007; 15 mg in study 2, p = 0.018).
30. Katz WA, Dube J: Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin. Ther. 10(2), 216-228 (1988).
31. SOMA® package insert. MedPointe Healthcare, Inc., NJ, USA (2007).
32. Parafon Forte® package insert. Ortho-McNeil Pharmaceuticals, Inc., NJ, USA (2009).
33. Skelaxin® package insert. King Pharmaceuticals, Inc., TN, USA (2008).
34. Robaxin® package insert. Schwarz Pharma AG, Monnheim, Germany (2003).
35. Orphengesic package insert. Par Pharmaceutical, Inc., NY, USA (1998).